Stockscreener 앱 받기
26.08
1.21%
-0.32
시간 외 거래:
26.46
0.38
+1.46%
전일 마감가:
$26.40
열려 있는:
$26.57
하루 거래량:
720.59K
Relative Volume:
0.81
시가총액:
$1.54B
수익:
$13.05M
순이익/손실:
$-60.54M
주가수익비율:
-22.48
EPS:
-1.16
순현금흐름:
$-37.82M
1주 성능:
-0.38%
1개월 성능:
+10.51%
6개월 성능:
-36.25%
1년 성능:
-41.63%
1일 변동 폭
$25.86
$27.26
1주일 범위
$25.29
$28.39
52주 변동 폭
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
26.08 | 1.55B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Is Janux Therapeutics Inc. a good long term investmentExceptional return forecasts - Autocar Professional
Janux Therapeutics Inc. Stock Analysis and ForecastExceptional profit potential - Autocar Professional
What drives Janux Therapeutics Inc. stock priceOverwhelming financial success - Autocar Professional
Strategic Initiatives and Long-Term Potential Drive Buy Rating for Janux Therapeutics Inc. - TipRanks
What analysts say about Janux Therapeutics Inc. stockDynamic profit expansion - Autocar Professional
Teacher Retirement System of Texas Sells 884 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Upgraded at Wall Street Zen - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $91.89 Consensus PT from Analysts - Defense World
E.W. Scripps (NASDAQ:SSP) Lowered to Sell Rating by Wall Street Zen - Defense World
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - BioSpace
Janux Therapeutics to Showcase New Preclinical Programs at Virtual R&D Day - AInvest
September 19th Options Now Available For Janux Therapeutics (JANX) - Nasdaq
How Janux Therapeutics Inc. stock performs during market volatilityExplosive Growth Potential - Newser
Why Janux Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Janux Therapeutics Inc. stock price move sharplyProfessional Stock Screener - Newser
Raymond James Financial Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World
Argus Initiates Coverage on CoreWeave (NASDAQ:CRWV) - Defense World
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Allspring Global Investments Holdings LLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Raymond James initiates Janux Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target - MarketScreener
Janux Therapeutics initiated with an Outperform at Raymond James - TipRanks
KBC Group NV Invests $66,000 in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
(JANX) On The My Stocks Page - news.stocktradersdaily.com
Janux Therapeutics Insiders Sell US$5.6m Of Stock, Possibly Signalling Caution - simplywall.st
Top Defense Stocks To Follow Now – July 1st - Defense World
2025's 10 Worst-Performing Stocks | Investing - US News Money
Janux Therapeutics: Riding Momentum into the Russell Indices and Beyond - AInvest
GAMMA Investing LLC Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
When (JANX) Moves Investors should Listen - news.stocktradersdaily.com
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - MSN
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
SG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics Becomes Oversold (JANX) - Nasdaq
Closing Figures Unveiled: Janux Therapeutics Inc (JANX) Drop -5.18, Closes at 23.61 - DWinneX
Janux Therapeutics, Inc. (JANX) Stock Analysis: Biotechnology Pioneer with 256.30% Potential Upside - DirectorsTalk Interviews
Capstone Holding Corp. (NASDAQ:CAPS), Secures $1 Million Pangaea Stone Order in Expanding Territory - The Globe and Mail
Where are the Opportunities in (JANX) - news.stocktradersdaily.com
Janux Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Janux Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Janux Therapeutics reports annual meeting results - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2025: In-depth Clinical - openPR.com
Equities Analysts Issue Forecasts for JANX FY2026 Earnings - Defense World
California State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics (NASDAQ:JANX) Shares Up 7.9% – Time to Buy? - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - Defense World
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):